Vistagen Therapeutics (NASDAQ:VTGN) Shares Pass Above 50-Day Moving Average – Time to Sell?

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) shares passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $2.84 and traded as high as $2.90. Vistagen Therapeutics shares last traded at $2.87, with a volume of 182,113 shares trading hands.

Vistagen Therapeutics Stock Up 2.1 %

The firm has a market capitalization of $84.56 million, a P/E ratio of -1.98 and a beta of 0.77. The firm’s 50-day simple moving average is $2.85 and its 200-day simple moving average is $2.98.

Vistagen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings data on Thursday, February 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.02. Vistagen Therapeutics had a negative net margin of 6,777.08% and a negative return on equity of 48.12%. The company had revenue of $230 billion during the quarter, compared to the consensus estimate of $0.18 million. As a group, analysts expect that Vistagen Therapeutics, Inc. will post -1.77 EPS for the current fiscal year.

Hedge Funds Weigh In On Vistagen Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of VTGN. HighTower Advisors LLC bought a new position in shares of Vistagen Therapeutics during the third quarter valued at about $64,000. Jane Street Group LLC bought a new position in Vistagen Therapeutics in the third quarter worth $59,000. Valence8 US LP bought a new position in shares of Vistagen Therapeutics in the 3rd quarter worth about $103,000. Virtu Financial LLC lifted its position in Vistagen Therapeutics by 30.5% during the 3rd quarter. Virtu Financial LLC now owns 20,210 shares of the company’s stock valued at $61,000 after acquiring an additional 4,722 shares during the period. Finally, Boothbay Fund Management LLC bought a new stake in Vistagen Therapeutics during the fourth quarter worth about $66,000. 78.39% of the stock is currently owned by hedge funds and other institutional investors.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.